By Colin Kellaher
Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of dollars to Stoke.
The biotechnology companies on Tuesday said they will work together to develop and commercialize zorevunersen outside of North America, with Biogen making an upfront payment of $165 million to Stoke.
As part of the agreement, Cambridge, Mass.-based Biogen will receive exclusive rest-of-world commercialization rights to zorevunersen, while Stoke, based in Bedford, Mass., retains exclusive rights the U.S., Canada and Mexico, the companies said.
Stoke is also eligible for up to $385 million in development and commercial milestone payments, along with royalties on potential sales in Biogen's territory.
The companies said Biogen will also chip in 30% of external clinical development costs for zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome, a genetic disorder characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments.
Stoke is on track to launch a global Phase 3 registrational study of zorevunersen in the second quarter, with a pivotal data readout expected in the second half of 2027 that is expected to support global regulatory filings, the companies said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 18, 2025 08:55 ET (13:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。